Analyst Reco. Verrica Pharmaceuticals Inc.

Equities

VRCA

US92511W1080

Market Closed - Nasdaq Other stock markets 04:00:03 2024-05-16 pm EDT			5-day change	1st Jan Change
9.13 ^USD	+0.33%		+16.45%	+24.73%

May. 15	Verrica Pharmaceuticals Amends Licensing Agreement With Torii Pharmaceutical for Phase 3 Trial of Ycanth	MT
May. 15	Verrica Pharmaceuticals Inc. Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study Ycanth for the Treatment of Common Warts	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Adjusts Price Target on Verrica Pharmaceuticals to $14 From $13, Maintains Buy Rating	May. 14	MT
Needham Adjusts Price Target on Verrica Pharmaceuticals to $16 From $8, Keeps Buy Rating	May. 14	MT
HC Wainwright Adjusts Verrica Pharmaceuticals Price Target to $13 From $12, Maintains Buy Rating	Mar. 01	MT
Needham Adjusts Verrica Pharmaceuticals' Price Target to $8 From $10, Maintains Buy Rating	Nov. 10	MT
HC Wainwright Adjusts Price Target on Verrica Pharmaceuticals to $12 From $11, Maintains Buy Rating	23-07-27	MT
RBC Boosts Price Target on Verrica Pharmaceuticals to $14 From $11 Amid 'Improved Company Positioning,' Keeps Outperform, Speculative Risk	23-07-25	MT
Needham Upgrades Verrica Pharmaceuticals to Buy From Hold, Price Target is $10	23-07-25	MT
Jefferies Initiates Verrica Pharmaceuticals at Buy With $10 Price Target	23-03-22	MT
Verrica Pharmaceuticals Upgraded by RBC to Outperform From Sector Perform, Price Target Boosted to $11 From $4, Speculative Risk Kept	23-02-13	MT
HC Wainwright Adjusts Verrica Pharmaceuticals' Price Target to $12 From $20, Maintains Buy Rating	22-05-31	MT
Needham & Co Downgrades Verrica Pharmaceuticals to Hold From Buy	22-05-25	MT
Needham Downgrades Verrica Pharmaceuticals to Hold From Buy	22-05-25	MT
Verrica Pharmaceuticals Shares Plumb New Depths After VP-102 Setback	22-05-25	DJ
RBC Downgrades Verrica Pharmaceuticals to Sector Perform From Outperform Amid Setback for VP-102, Cuts Price Target to $4 From $16; Speculative Risk Qualifier Kept	22-05-25	MT
Brookline Capital Markets Starts Verrica Pharmaceuticals at Buy With $20 Price Target	22-03-10	MT
Needham Adjusts Verrica Pharmaceuticals' Price Target to $18 from $20, Reiterates Buy Rating	22-03-03	MT
VERRICA PHARMACEUTICALS : HC Wainwright Cuts Price Target on Verrica Pharmaceuticals to $20 From $24, Maintains Buy Rating	21-09-22	MT
VERRICA PHARMACEUTICALS : Northland Securities Adjusts Verrica Pharmaceuticals PT to $18 From $19, Maintains Outperform Rating	21-09-21	MT
VERRICA PHARMACEUTICALS : Needham Cuts Price Target on Verrica Pharmaceuticals to $20 from $22, Keeps Buy Rating	21-09-21	MT
VERRICA PHARMACEUTICALS : RBC Cuts Price Target on Verrica Pharmaceuticals to $16 From $19 as FDA Notes Facility Issues; Outperform, Speculative Risk Kept	21-09-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Verrica Pharmaceuticals Inc.

Equities

VRCA

US92511W1080

Analyst Reco.

Filters